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Transfusion-related alloimmunization is a potent barrier to the engraftment of allogeneic hematopoietic stem
cells in patients with nonmalignant diseases (NMDs). Memory T cells, which drive alloimmunization, are rela-
tively resistant to commonly used conditioning agents. Alefacept, a recombinant leukocyte function antigen-3/
IgG1 fusion protein, targets CD2 and selectively depletes memory versus naive T cells. Three multiply trans-
fusedpediatric patientswithNMDreceiveda short courseofhigh-dose i.v. alefacept (.25mg/kg/dose ondays40
and9 and .5mg/kg/dose ondays33,26,19, and12) before undergoingunrelated allogeneic transplant in
the setting of reduced-intensity pretransplant conditioning and calcineurin inhibitorebased post-transplant
graft-versus-host disease (GVHD) prophylaxis. Alefacept infusions were well tolerated in all patients. Periph-
eral bloodﬂowcytometrywas performed at baseline and during and after alefacept treatment. As expected, after
the 5 weekly alefacept doses, each patient demonstrated selective loss of CD2hi/CCR7/CD45RA effector
memory (Tem) and CD2hi/CCR7þ/CD45RA central memory (Tcm) CD4þ and CD8þ T cells with relative preser-
vation of the CD2lo Tem and Tcm subpopulations. In addition, depletion of CD2þ natural killer (NK) cells also
occurred. Neutrophil recovery was rapid, and all 3 patients had 100% sorted (CD3/CD33) peripheral blood donor
chimerismbydayþ100. Immune reconstitution (byabsolute neutrophil,monocyte, and lymphocyte counts)was
comparablewitha cohortofhistorical control patients. All 3 patients developedGVHDbut are all nowoff immune
suppression and >2 years post-transplant with stable full-donor engraftment. These results suggest that alefa-
cept athigherdosingcandeplete bothmemoryTcells andNKcells and that incorporatingCD2-targeteddepletion
into a reduced-intensity transplant regimen is feasible and safe in heavily transfused patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapy for many pediatric pa-
tients with life-threatening nonmalignant diseases (NMDs)
[1-14]. Rejection remains an impediment to successful
transplantation in many of these disorders, especially in
Table 1
Clinical Characteristics and Outcomes
Patient
No.
Age
(yr)/Sex
Disease Erythrocyte
Transfusions*
Platelet
Transfusions*
Previous
alloimmunization (Y/N)
HLA
Antibody
Screen (þ/)
HLA
Matching
(Mismatch)
CMV
Status (R/D)
Graft
Source
1 2/F Dyskeratosis congenita
with bone marrow failure
17 42 N  5/6
(B antigen)
þ/þ CB
2 10/M Fanconi anemia with bone
marrow failure
16 12 Y þ{ 5/6 / CB
3 9/F Idiopathic SAAyy 15 27 N  (B antigen)
8/8
/ BM
CMV indicates cytomegalovirus; CB, cord blood.
* Approximate, before transplantation.
y All regimen-related toxicities were determined to be unlikely attributable to the study drug.
z Infections were determined to be possibly attributable to the study drug.
x aGVHD of the skin and gut, diagnosed on day þ27, maximal grade III.
k Pulmonary aspergillosus by computed tomography diagnosis only, day þ10. CMV viremia diagnosed day þ27, initially treated with ganciclovir, recurrent
viremia (ganciclovir resistant) resolved with foscarnet. Bacterial sinusitis, diagnosed day þ41.
{ Panel reactive antibody positive at class I (25%) with speciﬁcity for A30 and A31 (not donor directed).
# aGVHD of the skin, diagnosed on day þ20, maximal grade II.
** Bacteremia with Streptococcus viridians day þ1 and Staphylococcus epidermidis day þ32.
yy Failing immune suppressive therapy, no matched sibling donor.
zz CD3 chimerism was followed monthly and was 100% on day þ147.
xx aGVHD of the skin, diagnosed on day þ22, maximal grade II.
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reduced-intensity conditioning [15-18]. Because most of
these patients require multiple erythrocyte and/or platelet
transfusions as part of their routine medical care before
HSCT, transfusion-related alloimmunization to minor and
major histocompatibility antigens likely accounts for part of
their risk for graft rejection [19-23]. Biologically, memory T
cells have been shown to underlie this sensitization to donor
antigens and to drive graft rejection [22-24]. Natural killer
(NK) cells have also been shown to induce potent transplant
rejection in murine models and patients [25-27], especially
in the setting of limiting stem cell doses, with the NK cell
immunoglobulin-like receptor ligand group correlating with
risk of rejection [28,29].
Alefacept (Amevive; Astellas, Inc., Northbrook, IL, USA) is
a recombinant leukocyte function antigen-3 (LFA-3)/IgG1
fusion protein that targets CD2, thereby depleting CD2-
expressing cells via antibody-dependent cellular cytotox-
icity (ADCC) [30-36]. Alefacept is well tolerated and has
been previously demonstrated to produce a gradual and
dose-dependent reduction in memory T cells (that highly
express CD2), which plateaus 5 to 6 weeks after drug
administration [36]. The phase III study of alefacept in
psoriasis used a mid-range dose of 7.5 mg (.15 mg/kg for a
50-kg adult) weekly for 12 weeks. The mid-range dosing
strategy was chosen for psoriasis patients due to concerns
regarding the potential infectious risks associated with the
more signiﬁcant CD4 depletion that occurred with higher
doses, and this was the dose ultimately approved by the US
Food and Drug Administration in 2003. Given the link be-
tween memory T cellemediated alloimmunization and
HSCT rejection and the ability of alefacept to selectively
deplete these cells, we hypothesized that alefacept admin-
istration before the start of conditioning might safely and
effectively counter the risk of rejection in multiply trans-
fused patients with NMDs. Based on the dose-dependent
reduction in memory T cells demonstrated in the dose-
ﬁnding study in psoriasis [36], we additionally reasoned
that dose escalation beyond the highest dose in
the previous trials might maximize the beneﬁt of alefacept
preconditioning in a patient population in which post-
transplant reconstitution with donor T cells wouldmitigate any long-term risks of alefacept-induced T cell
depletion.
To begin to test these hypotheses, we launched a pilot
study of alefacept given at a dose of .5 mg/kg/dose weekly
for 5 weeks during transplant preconditioning in multiply
transfused children receiving reduced-intensity conditioning
and unrelated donor transplant for nonmalignant hemato-
logic disorders. Herein we report our results, both clinical
and mechanistic, in the ﬁrst 3 patients we enrolled on this
study. Unfortunately, the manufacturer terminated produc-
tion of alefacept for ﬁscal reasons during the conduct of this
study, thus prompting premature interruption of the trial.
Results in the ﬁrst 3 patients demonstrate that full donor
engraftment was achieved in all cases, and ﬂow cytometry
demonstrated depletion of both memory T cells and NK cells
during alefacept treatment. These results suggest biologic
activity of alefacept in pediatric HSCT patients and argue for
renewed development of CD2-targeted agents for HSCT
patients at high risk of transplant rejection.
METHODS
Study Design and Patients
This was a single-arm pilot study with an accrual goal of 5 patients.
Patients were enrolled at the Aﬂac Cancer and Blood Disorders Center
within Children’s Healthcare of Atlanta (CHOA). The trial was registered at
clinicaltrials.gov (NCT01319851) and approved by the Institutional Review
Board at CHOA and Emory University. Investigational New Drug exemption
was obtained for the administration of alefacept. Eligibility criteria included
signed informed consent, age 0 to 21 years, NMD requiring at least 5
transfusions (platelet, erythrocyte, or granulocyte units), adequate organ
function,7/8matched related or unrelated bonemarrow donor (HLA-A, -B,
-C, and -DR; antigen or allele mismatch was permitted) or 5/6 cord blood
unit (HLA-A, -B, and -DRB1; allele mismatch permitted except at -DRB1)
with a recommended dose of 5  107 total nucleated cells (TNCs)/kg
recipient weight, and an HLA antibody screen negative for disparate HLA
molecules (in patients with partially HLA-matched allografts). The study
was closed to accrual in 2012 after Astellas discontinued production of
alefacept and the drug became unavailable.
Treatment Protocol
Alefacept preconditioning
All patients received alefacept .5 mg/kg/dose i.v., with the ﬁrst dose split
on days40 and39 and the remaining doses given on days33,26,19,
and12 (eg, weekly for 5 doses). Alefaceptwas diluted in sterilewater (2mL
total volume) and administered via i.v. push followed by a normal saline
ﬂush per the package insert.
Cell Dose
(TNC/kg)
Infusional
Reaction
Grades 2-3
RRTy to
Day þ42
Neutrophil
Engraftment (days)
Day þ30
Chimerism
(CD3/CD33)
Grades
II-IV
aGVHD (Y/N)
Mild
cGVHD
(Y/N)
Moderate
cGVHD
(Y/N)
Severe
cGVHD
(Y/N)
Infection to Day þ100z Follow-up
(days)
11.9  107 N Stomatitis
(grade 2)
13 100/100 Yx N N Y Pulmonary aspergillosus,
CMV viremia, sinusitisk
1293
4.6  107 N Stomatitis 17 100
(unfractionated)
Y# N Y N Bacteremia** 915
4.6  108 N (grade 2)
None
20 85/100zz Yxx N N N None 904
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Patients with Fanconi anemia (FA) received ﬂudarabine 25 mg/m2 on
days10 to5 and cyclophosphamide 10 mg/kg on days5 to2. All other
patients receivedﬂudarabine 25mg/m2 ondays6 to1, cyclophosphamide
50mg/kgonday2, and200cGy total body irradiationonday1.All patients
received cyclosporine and mycophenolate mofetil for graft-versus-host dis-
ease (GVHD) prophylaxis beginning on day2. Cyclosporine was adjusted to
maintain an infusional or trough level of 200 to300ng/mLandwas continued
through at least day þ180. Mycophenolate mofetil was administered at 15
mg/kg/dose (p.o. or i.v.) 3 times daily through at least day þ45.Clinical Endpoints
The primary objective of this study was to determine the feasibility
of administering the 6 doses of alefacept to multiply transfused pediatric
patients with NMD undergoing HSCT. In addition, infusional reactions, grade
2 or greater regimen-related toxicities (RRT; through day þ42, according to
Bearman criteria), graft failure (primary and secondary), graft loss, acute and
chronic GVHD (using National Institutes of Health consensus criteria), and
unexpected serious adverse events were captured.Immune Monitoring
Longitudinal ﬂow cytometric analyses included the enumeration of NK
cells (CD3/CD20/CD16þ/CD56hi/lo) and CD20/CD3þ/CD4þ/CD8 and
CD20/CD3þ/CD4/CD8þ T cells, including naive (CCR7þ/CD45RAþ), central
memory (Tcm; CCR7þ/CD45RA), effector memory (Tem; CCR7/CD45RA),
and terminal effector memory subsets (Temra; CCR7/CD45RAþ). T cell
subsets were divided into CD2hi (alefacept target cells) and CD2lo. The
antibody clones used for the ﬂow cytometric analysis are as follows: CD3
(UCHT1; Becton Dickinson, Franklin Lakes, NJ), CD20 (H147; Invitrogen,
Grand Island, NY), CD16 (3G8; Becton Dickinson), CD56 (B159; Becton
Dickinson), CD8 (RPA-T8; eBioscience, San Diego, CA), CD4 (RPA-T4; Becton
Dickinson), CD2 (RPA-2.10; Becton Dickinson), CD45RA (MEM-56; Invi-
trogen), and CCR7 (3D12; Becton Dickinson). Testing was performed on
samples from days40,26,6, and 0 using a minimum of 100,000 events.
TruCount beads (Becton Dickinson) were used to generate cell counts.Retrospective Control Subjects
To provide clinical and laboratory data for comparison, we obtained data
on 23 patients who did not participate in this trial and received unrelated
(marrow or cord blood) HSCT at CHOA for marrow failure (acquired or
inherited) after 2000. This was approved by the CHOA Institutional Review
Board.Statistical Analysis
Statistical analyses were performed using Prism version 5 for Mac OS X
(GraphPad Software, La Jolla, CA). Paired t-tests were used to calculate
P values comparing baseline immunologic values with those after all doses
of alefacept were given and before transplant conditioning.RESULTS
Patient Characteristics and Clinical Outcomes
Three patients were enrolled. Patient 1 was a 2-year-old
girl with dyskeratosis congenita (DKC) and marrow failure
requiring 17 erythrocyte and 42 platelet transfusions before
undergoing 5/6 unrelated cord blood transplant with a cell
dose of 11.9  107 TNCs/kg (Table 1). She tolerated her
alefacept infusions without complication. Post-HSCT she
developed grade 2 RRT consisting of stomatitis. Peripheral
blood donor chimerism (CD3 and CD33) was 100% on
day þ30 post-transplant and on all subsequent analyses
(Table 1; last analysis at 2 years post-transplant). On dayþ27
shewas diagnosed with acute GVHD (aGVHD) of the skin and
gastrointestinal tract (maximal grade III) that responded to
systemic steroid treatment. She developed severe chronic
GVHD (cGVHD) with involvement of the gastrointestinal
tract and heart (recurrent pericardial effusions, possibly
serositis), which was treated with steroids and drainage
due to cardiac tamponade. Both of these cGVHD sequelae
ultimately resolved. She had several infections post-HSCT,
including pulmonary aspergillosus, recurrent cytomegalo-
virus viremia, and bacterial sinusitis, all of which responded
to treatment. She is currently off immune suppression and
without GVHD approximately 3.5 years post-transplant. She
has developed chronic restrictive pulmonary disease,
requiring nasal cannula oxygen, and hepatic ﬁbrosis, both
attributed to DKC.
Patient 2 was a 10-year-old boy with FA and marrow
failure requiring 16 erythrocyte and 12 platelet transfusions
before undergoing 5/6 unrelated cord blood transplant with
cell dose of 4.6  107 TNCs/kg (Table 1). His panel reactive
antibody screen was positive at class I (25%) before HSCT
with speciﬁcity for A30 and A31, neither of which were
donor-directed. He tolerated his alefacept infusions without
complication. Post-HSCT he developed grade 2 RRT (sto-
matitis). Sorted (CD3 and CD33) peripheral blood chime-
rism studies demonstrated 100% donor chimerism on
day þ30 post-transplant and on all subsequent analyses
(Table 1; last analysis at 13 months post-transplant). He
developed aGVHD of the skin on day þ20 that was maxi-
mally grade II and that responded to systemic steroids. The
patient developed moderate cGVHD with involvement of
Figure 1. Impact of alefacept preconditioning on post-transplant hematologic reconstitution. Hematologic reconstitution was monitored in all 3 patients receiving
alefacept treatment and compared with a cohort of 23 historical control subjects. Black circles indicate patient 1; blue squares, patient 2; red triangles, patient 3; black
diamonds (with broken line), historical control subjects (mean  SEM). (This ﬁgure is available in color online at www.bbmt.org).
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therapies. He had 2 episodes of bacteremia post-HSCT,
including with Streptococcus viridans on day þ1 and
Staphylococcus epidermidis on day þ32, both of which
resolved with i.v. antibiotics. He is currently approximately
2.5 years from transplant and off immune suppression
without signs of cGVHD.
Patient 3 was a 9-year-old girl with idiopathic severe
aplastic anemia (SAA) requiring 15 erythrocyte and 27
platelet transfusions before undergoing 8/8 matched unre-
lated bone marrow transplant with cell dose of 4.6  108
TNCs/kg (Table 1). She tolerated her alefacept infusions
without complication. There was no RRT. She had 85% CD3
and 100% CD33 donor chimerism on day þ30; subsequent
analyses showed 100% CD3 chimerism by day þ147 with the
last analysis at 1 year post-transplant (Table 1; CD3 and CD33
both 100% donor at that time). The patient developed aGVHD
of the skin on day þ22 that was maximally grade II and
that resolved with systemic steroids. She did not develop
cGVHD or have any infections post-HSCT. She is currently
approximately 2.5 years post-transplant and without
symptoms of GVHD off immune suppression.
The retrospective control group comprised 23 patients
who received unrelated marrow or cord blood (single or
double) transplants for a variety of diseases, including SAA,
FA, DKC, Diamond-Blackfan anemia, and Shwachman-
Diamond syndrome. Four (17.4%) patients suffered rejection.
Post-Transplant Leukocyte Reconstitution
As shown in Figure 1, the leukocyte reconstitution
(WBC, absolute neutrophil count [ANC], absolute monocyte
count [AMC], and absolute lymphocyte count [ALC]) of the
3 patients was similar to that of the retrospective control
subjects. Neutrophil engraftment (ﬁrst-day ANC > 500 cells/
mL for 3 consecutive days) occurred on days þ13, þ17,
and þ21 in the 3 trial patients and at a median of 21 days
(1.2 days) in the control subjects. An AMC > 200 cells/mL
was achieved in the trial patients on days þ12, þ16, and þ15
and at a median of þ18.8 days (1.0 days) in the controlsubjects. An ALC > 1000 cells/mL was achieved in the trial
patients by days þ17, þ60, and þ435; in historical control
subjects, ALC > 1000 cells/mL was achieved by 20%, 47%,
80%, and 100% by days þ60, þ100, and þ180 and 1 year,
respectively.
Pharmacodynamic Monitoring of the Pretransplant
Impact of Alefacept on T Cells and NK Cells
Flow cytometry was performed on peripheral blood
samples during the alefacept treatment preconditioning
phase as follows: baseline (day 40, before the ﬁrst dose of
alefacept), during alefacept (day26, before the third dose of
alefacept), and after the ﬁnal dose of alefacept but before
the start of conditioning (on day 6 or 10 depending on
the conditioning regimen used) and before transplant
(day 0). Hematologic and immune monitoring included the
enumeration of WBC, ANC, AMC, NK cell count, total T and B
lymphocyte counts, and the proportion and absolute number
of CD4 and CD8 T cell subsets.
Patients 1 and 3 demonstrated no statistically signiﬁcant
change in the WBC, ANC, ALC, AMC, T lymphocyte, and B
lymphocyte counts or their relative proportions during the
alefacept treatment (Figure 1, P > .1 for all analyses when
data combined). Patient 2 did demonstrate a decline in the
number of WBC, granulocytes, and T and B lymphocytes with
stable monocyte counts during this time period. Of note,
although this patient had testing for FA at initial diagnosis
that was inconclusive (and therefore received SAA-type
therapy for bone marrow failure before HSCT), repeat
testing before transplant conﬁrmed a diagnosis of FA. During
treatment for aplastic anemia, patient 2 had received
antithymocyte globulin (horse and rabbit) and cyclosporine,
which were given 6 to 12 months before receiving alefacept.
In addition, he was receiving granulocyte-colony stimulating
factor and low-dose prednisone (<.2 mg/kg/day) daily dur-
ing alefacept preconditioning.
To determine the impact of alefacept preconditioning on
CD4þ and CD8þ cells, the CD4þ and CD8þ T naive, Tem, Tcm,
and Temra were divided into CD2hi (putative alefacept target
Figure 2. Impact of alefacept preconditioning on CD4þ and CD8þ naive andmemory Tcell subsets and on NK cells. Longitudinal immunemonitoringwas performed on
peripheral blood samples using ﬂowcytometry. Samples were drawn at baseline (day40, before the ﬁrst dose of alefacept), during alefacept (day26, before the third
dose of alefacept), after the ﬁnal dose of alefacept but before the start of conditioning (on day 6 or 10 depending on the conditioning regimen used), and before
transplant (day 0). CD20/CD3þ/CD4þ/CD8 and CD20/CD3þ/CD4/CD8þ T cells were divided into naive (CCR7þ/CD45RAþ), Tcm (CCR7þ/CD45RA), Tem (CCR7/
CD45RA), and Temra (CCR7/CD45RAþ). Tcell subsetswere further divided into CD2hi (alefacept target cells) and CD2lo. NK cells were classiﬁed as CD3/CD20/CD16þ/
CD56hi/lo. Black circles indicate patient 1; blue squares, patient 2; red triangles, patient 3. Solid lines denote CD2hi cells and dashed lines denote CD2lo cells. *P  .05
comparing baseline with post-alefacept values on combined data. (A) Top panels showcomparison of the percent of CD4þ T naive, Tcm, Tem, and Temra that were CD2hi
for each patient at baseline and after all alefacept doses were completed. Bottom panels show comparison of absolute numbers (cells/mL) of CD4þ T naive, Tcm, Tem, and
Temra thatwereCD2hi for each patient at baseline and after all alefacept doseswere completed. (B) Toppanels showcomparison of the percent of CD8þ Tnaive, Tcm, Tem,
and Temra that were CD2hi for each patient at baseline and after all alefacept doses were completed. Bottom panels show comparison of absolute numbers (cells/mL) of
CD8þ T naive, Tcm, Tem, and Temra that were CD2hi for each patient at baseline and after all alefacept doses were completed. (C) Top panels show comparison of the
percentage of total lymphocytes attributed to NK cells or NK cell subpopulations for each patient at baseline and after all alefacept doseswere completed. Bottompanels
show comparison of the absolute number of NK cells or NK cell subpopulations (cells/mL) for each patient at baseline and after all alefacept doses were completed. (This
ﬁgure is available in color online at www.bbmt.org).
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and B) [37]. As shown in Figure 2, all 3 patients had a
decrease in the frequency of CD2hi CD4þ Tcm and Temra and
of CD2hi CD8þ Tcm and Tem (which, even for this small
number of patients, reached statistical signiﬁcance, P < .05
for all combined analyses). The frequency of the more rare
CD2hi CD4þ Tem and CD8þ Temra populations declined in
all 3 patients, although this was not statistically signiﬁcant
(P ¼ .09 and .08, respectively, on combined data).
Although the absolute number of the CD2hi cells also
declined during alefacept treatment, this did not reach sta-
tistical signiﬁcance.
Given their ubiquitous expression of CD2, NK cells,
including both CD56lo and CD56hi subsets, were examined
during preconditioning with alefacept. The frequency and
number of all NK cells decreased during alefacept treatment
in all 3 patients (Figure 2C), with the largest decline observed
in patient 1. The absolute number of the CD56hi NK subset
likewise decreased in all 3 patients, and the frequency of
these cells decreased in patients 1 and 3.
DISCUSSION
This is the ﬁrst study to report the use of alefacept, a
recombinant LFA-3/IgG1 fusion protein targeting CD2, as a
component of the conditioning regimen in patients under-
going HSCT. We report the clinical outcomes and immune
effects of alefacept preconditioning in our ﬁrst 3 patients
before the drug was removed from production by the
drug company in 2011. Alefacept was well tolerated in this
study, with no infusional reactions or drug-related toxicity.
Although all 3 patients were at heightened risk for graft
rejection by virtue of their NMDs, their extensive transfusion
history, the use of mismatched donors (2 being 5/6 cord
blood units), and the use of a reduced-intensity conditioning
regimen, all 3 achieved sustained, full-donor engraftment
[15-17,19-23,38].
In this series we found that alefacept decreased memory
T cell subsets, predominantly in CD8þ Tcells, had no effect on
naive T cells, and led to a decrease in NK cells. All 3 patients
had a notable decline in the percentage of CD2hi CD8þ
memory cell subsets, which was statistically signiﬁcant for
Tcm and Tem. This corresponded to an individual decline
in the number of CD2hi CD8þ Tem and Temra cells in all 3
patients. Consistent with the expression of CD2 on NK cells,
we also observed a decrease in both the absolute numbers
and proportions of these cells in all 3 patients.
Animal models indicate that in the setting of MHC-
matched transplantation, rejection induced by transfusion-
related alloimmunization is mediated primarily by T cells
[39]. Given the challenges to demonstrating donor-directed
cellular immunity clinically, we did not attempt to assess
it. Therefore, we cannot ascertain the extent to which
pretransplant transfusions may have posed a barrier to
engraftment in our 3 patients. Although a much larger study
would be needed to accurately gauge alefacept’s efﬁcacy, that
all 3 patients achieved full donor engraftment nevertheless
raises the possibility that it might promote engraftment,
especially because the incidence of rejectionwas 17.4% in our
control group. Also, even higher incidences have been
observed in registry studies of unrelated HSCT for FA, DKC,
and other forms of marrow failure [10,17,40].
The immune effects of alefacept have been described
primarily in psoriasis and after solid organ transplant
[30,36,41-43], although its use has recently been reported in
pediatric patients with newly diagnosed type 1 diabetesmellitus [44]. In these populations, alefacept was found to
predominantly decrease CD4þ and CD8þ memory T cells
with only a modest depletion of NK cells [41,42]. Although
NK cells are uniformly CD2 high [45-47] and therefore should
be targeted by alefacept, previous studies have not demon-
strated any signiﬁcant effect [41,42]. However, unlike in
psoriasis, solid organ transplant, and type 1 diabetes, our
study used a higher dose of alefacept and shorter total
course. Although our data do not speciﬁcally address this, it
is possible that this higher alefacept dose was able to more
efﬁciently target NK cells than the lower doses used in pre-
vious studies. This represents an important area for future
investigation.
Of note, the degree of memory T cell depletion was also
lower in this study compared with previous results in pso-
riasis patients, where alefacept led to a steep decline in CD4þ
and CD8þ memory T cell counts (CD45ROþ) [30,36]. The
decrease in memory T cells continued through the 12 weeks
of therapy in the psoriasis patients; however, most of the
decline occurred in the ﬁrst 6 weeks of therapy with counts
dropping by greater than 50% [30,36]. Given that depletion of
memory T cells by alefacept has been shown to rely on ADCC,
which is prominently mediated by NK cells [46], it is possible
that the current regimen favored depletion of NK cells. Also,
with fewer of these cells available, ADCC of memory T cell
populations was less effective. Although depletion of NK cells
may have beneﬁcial effects on engraftment, it is important to
note that NK cells have also been shown to be integral to
tumor and viral immunity post-HSCT [48] and that there
have been selected reports of malignancy in patients
receiving long-term alefacept for autoimmune indications
[43,49].
Two limitations of our study beyond its small size are that
we did not perform pharmacokinetic testing and did not
rigorously assess immune reconstitution. Together, these
limitations make it difﬁcult to determine to what extent if
any that alefacept may have hindered immune reconstitu-
tion. Further studies with this drug, or other agents targeting
CD2, would beneﬁt from a detailed analysis of pharmacoki-
netics, a determination of the impact of pretransplant
treatment on post-transplant reconstitution of NK and T cells
subsets, and functional immune studies (including response
to vaccines) in treated patients.
In addition to alefacept, other agents, such as antibodies
directed against LFA-1 (efalizumab) [50,51] or CD2 (siplizu-
mab) [51-54], have been studied with the goal of depleting
memory T cells. However, unlike alefacept, these drugs do
not selectively deplete memory T cells and may have more
serious off-target effects on protective immunity to new
pathogens [55]. Unfortunately, in 2011 production of alefa-
cept was halted based on ﬁscal, not clinical, factors. This
decision has had a signiﬁcant negative impact on multiple
ﬁelds in addition to HSCT, including systemic autoimmune
disease, solid organ transplant, and type 1 diabetes [42-
44,56]. The results of the current case series add to the
strong rationale for reviving alefacept or similar agents,
which deserve expanded analysis for their utility in multiple
immune-mediated diseases. This case series also suggests
that further studies using higher dosing schedules of alefa-
cept may impact NK cells in addition to memory T cells and
that an escalating dose of alefacept may alter the cell types
targeted to favor either memory T cells or NK cells. This may
make a signiﬁcant clinical impact on patients undergoing
HSCT for NMDs who are at high risk for rejection by both
innate and adaptive immune mechanisms.
E.O. Stenger et al. / Biol Blood Marrow Transplant 21 (2015) 1839e1855 1851ACKNOWLEDGMENTS
Financial disclosure: This work was supported by the
ACTSI KL2-Mentored Clinical and Translational Research
Program (to E.O.S.) and the National Institutes of Health
grant KL2TR000455 (to E.O.S.).
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: E. O. S. and K.-Y. C. are coeﬁrst
authors. L. K. and J. H. are coesenior authors.REFERENCES
1. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related
myeloablative stem-cell transplantation to cure sickle cell disease.
Blood. 2007;110:2749-2756.
2. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation
in patients with thalassemia. N Engl J Med. 1990;322:417-421.
3. Bellucci S, Damaj G, Boval B, et al. Bonemarrow transplantation in severe
Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bone
Marrow Transplant. 2000;25:327-330.
4. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term
outcome following hematopoietic stem-cell transplantation in
Wiskott-Aldrich syndrome: collaborative study of the European Society
for Immunodeﬁciencies and European Group for Blood and Marrow
Transplantation. Blood. 2008;111:439-445.
5. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic
granulomatous disease with myeloablative conditioning and an un-
modiﬁed hemopoietic allograft: a survey of the European experience,
1985-2000. Blood. 2002;100:4344-4350.
6. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients
with severe congenital neutropenia without evidence of leukemic
transformation. Blood. 2000;95:1195-1198.
7. Qasim W, Cavazzana-Calvo M, Davies EG, et al. Allogeneic hemato-
poietic stem-cell transplantation for leukocyte adhesion deﬁciency.
Pediatrics. 2009;123:836-840.
8. Donadieu J, Michel G, Merlin E, et al. Hematopoietic stem cell trans-
plantation for Shwachman-Diamond syndrome: experience of the
French neutropenia registry. Bone Marrow Transplant. 2005;36:
787-792.
9. Roy V, Perez WS, Eapen M, et al. Bone marrow transplantation for
diamond-blackfan anemia. Biol Blood Marrow Transplant. 2005;11:
600-608.
10. Wagner JE, Eapen M, MacMillan ML, et al. Unrelated donor bone
marrow transplantation for the treatment of Fanconi anemia. Blood.
2007;109:2256-2262.
11. Ghavamzadeh A, Alimoghadam K, Nasseri P, et al. Correction of bone
marrow failure in dyskeratosis congenita by bone marrow trans-
plantation. Bone Marrow Transplant. 1999;23:299-301.
12. Eapen M, DeLaat CA, Baker KS, et al. Hematopoietic cell transplantation
for Chediak-Higashi syndrome. Bone Marrow Transplant. 2007;39:
411-415.
13. Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic
cell transplantation for hemophagocytic lymphohistiocytosis. Bone
Marrow Transplant. 2008;42:175-180.
14. Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor
stem cell transplantation for children with severe aplastic anemia. Br
J Haematol. 2008;141:216-223.
15. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide,
antithymocyte globulin, with or without low dose total body irradia-
tion, for alternative donor transplants, in acquired severe aplastic
anemia: a retrospective study from the EBMT-SAA Working Party.
Haematologica. 2010;95:976-982.
16. Peffault de Latour R, Porcher R, Dalle JH, et al. Allogeneic hematopoietic
stem cell transplantation in Fanconi anemia: the European Group for
Blood and Marrow Transplantation experience. Blood. 2013;122:
4279-4286.
17. Gadalla SM, Sales-Bonﬁm C, Carreras J, et al. Outcomes of allogeneic
hematopoietic cell transplantation in patients with dyskeratosis con-
genita. Biol Blood Marrow Transplant. 2013;19:1238-1243.
18. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood
transplantation for children with severe sickle cell disease: results of
one cohort from the phase II study from the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow
Transplant. 2012;18:1265-1272.
19. Storb R, Raff RF, Appelbaum FR, et al. The inﬂuence of transfusions from
unrelated DLA-matched or mismatched donors upon marrow grafts
between DLA-identical canine littermates. Transplantation. 1988;46:
334-336.
20. Storb R, Deeg HJ, Appelbaum FR, et al. The biology of graft rejection in a
canine model of marrow transplantation. Transplant Proc. 1987;19:
18-22.21. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure
following bone marrow transplantation for severe aplastic anemia: risk
factors and treatment results. Blood. 1989;73:606-613.
22. Desmarets M, Cadwell CM, Peterson KR, et al. Minor histocompatibility
antigens on transfused leukoreduced units of red blood cells induce
bone marrow transplant rejection in a mouse model. Blood. 2009;114:
2315-2322.
23. Patel SR, Cadwell CM, Medford A, Zimring JC. Transfusion of minor
histocompatibility antigen-mismatched platelets induces rejection
of bone marrow transplants in mice. J Clin Invest. 2009;119:2787-
2794.
24. Storb R, Deeg HJ. Failure of allogeneic canine marrow grafts after total-
body irradiation. Allogeneic “resistance” versus transfusion-induced
sensitization. Transplantation. 1986;42:571-580.
25. Kean LS, Hamby K, Koehn B, et al. NK cells mediate costimulation
blockade-resistant rejection of allogeneic stem cells during non-
myeloablative transplantation. Am J Transplant. 2006;6:292-304.
26. Hamby K, Trexler A, Pearson TC, et al. NK cells rapidly reject allogeneic
bonemarrow in the spleen throughaperforin- and Ly49D-dependent, but
NKG2D-independent mechanism. Am J Transplant. 2007;7:1884-1896.
27. Chow T, Whiteley J, Li M, Rogers IM. The transfer of host MHC class I
protein protects donor cells from NK cell and macrophage-mediated
rejection during hematopoietic stem cell transplantation and engraft-
ment in mice. Stem Cells. 2013;31:2242-2252.
28. Moretta L, Locatelli F, Pende D, et al. Killer Ig-like receptor-mediated
control of natural killer cell alloreactivity in haploidentical hemato-
poietic stem cell transplantation. Blood. 2011;117:764-771.
29. Littera R, Orru N, Caocci G, et al. Interactions between killer
immunoglobulin-like receptors and their human leucocyte antigen
Class I ligands inﬂuence the outcome of unrelated haematopoietic stem
cell transplantation for thalassaemia: a novel predictive algorithm. Br
J Haematol. 2012;156:118-128.
30. Gordon KB, Vaishnaw AK, O’Gorman J, et al. Treatment of psoriasis with
alefacept: correlation of clinical improvement with reductions of
memory T-cell counts. Arch Dermatol. 2003;139:1563-1570.
31. Lebwohl M. Combining the new biologic agents with our current
psoriasis armamentarium. J Am Acad Dermatol. 2003;49:S118-S124.
32. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immuno-
modulatory recombinant LFA-3/IgG1 fusion protein, induces CD16
signaling and CD2/CD16-dependent apoptosis of CD2(þ) cells.
J Immunol. 2002;168:4462-4471.
33. Majeau GR, Meier W, Jimmo B, et al. Mechanism of lymphocyte
function-associated molecule 3-Ig fusion proteins inhibition of T cell
responses. Structure/function analysis in vitro and in human CD2
transgenic mice. J Immunol. 1994;152:2753-2767.
34. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and
tolerability of alefacept by intravenous and intramuscular adminis-
tration. J Pharmacokinet Pharmacodyn. 2002;29:415-426.
35. Kaplon RJ, Hochman PS, Michler RE, et al. Short course single agent
therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac
allograft survival. Transplantation. 1996;61:356-363.
36. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of
chronic plaque psoriasis by selective targeting of memory effector T
lymphocytes. N Engl J Med. 2001;345:248-255.
37. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human
alloresponsive CD8þ effector memory T cells based on CD2 expression.
Am J Transplant. 2011;11:22-33.
38. Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern
era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:
537-543.
39. Patel SR, Zimring JC. Transfusion-induced bone marrow transplant
rejection due to minor histocompatibility antigens. Transfus Med Rev.
2013;27:241-248.
40. Bizzetto R, Bonﬁm C, Rocha V, et al. Outcomes after related and un-
related umbilical cord blood transplantation for hereditary bone
marrow failure syndromes other than Fanconi anemia. Haematologica.
2011;96:134-141.
41. Larsen R, Ryder LP, Svejgaard A, Gniadecki R. Changes in circulating
lymphocyte subpopulations following administration of the leucocyte
function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Clin Exp Immunol. 2007;149:23-30.
42. LeeS,YamadaY,TonshoM,etal.Alefaceptpromotes immunosuppression-
free renal allograft survival in nonhuman primates via depletion of
recipient memory T cells. Am J Transplant. 2013;13:3223-3229.
43. Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with
tacrolimus, mycophenolate mofetil and steroids in de novo kidney
transplantation: a randomized controlled trial. Am J Transplant. 2013;
13:1724-1733.
44. Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells
with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month
results of a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Diabetes Endocrinol. 2013;1:284-294.
45. Comerci CJ, Mace EM, Banerjee PP, Orange JS. CD2 promotes human
natural killer cell membrane nanotube formation. PloS One. 2012;7:
e47664.
M. Koren-Michowitz et al. / Biol Blood Marrow Transplant 21 (2015) 1839e1855185246. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, puriﬁca-
tion, and functional assessment of human peripheral blood NK cells.
J Visual Exp. 2011;48:1-5.
47. Ortaldo JR, Mason A, Willette-Brown J, et al. Modulation of lymphocyte
function with inhibitory CD2: loss of NK and NKT cells. Cell Immunol.
2007;249:8-19.
48. Foley B, Felices M, Cichocki F, et al. The biology of NK cells and their
receptors affects clinical outcomes after hematopoietic cell trans-
plantation (HCT). Immunol Rev. 2014;258:45-63.
49. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis
and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017.
50. Badell IR, Russell MC, Thompson PW, et al. LFA-1-speciﬁc therapy
prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120:
4520-4531.
51. Reisman NM, Floyd TL, Wagener ME, et al. LFA-1 blockade induces
effector and regulatory T-cell enrichment in lymph nodes and syner-
gizes with CTLA-4Ig to inhibit effector function. Blood. 2011;118:
5851-5861.Financial disclosure: See Acknowledgments on page 1854.
* Correspondence and reprint requests: Maya Koren-Michowitz, Division
of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-
Gan 52621, Israel.
E-mail address:m.koren.michowitz@gmail.com (M. Koren-Michowitz).
http://dx.doi.org/10.1016/j.bbmt.2015.06.018
1083-8791/ 2015 American Society for Blood andMarrow Transplantation.52. Adkins D, Ratanatharathorn V, Yang H, White B. Safety proﬁle and
clinical outcomes in a phase I, placebo-controlled study of siplizumab
in acute graft-versus-host disease. Transplantation. 2009;88:198-202.
53. Pruett TL, McGory RW, Wright FH, et al. Safety proﬁle, pharmacoki-
netics, and pharmacodynamics of siplizumab, a humanized anti-CD2
monoclonal antibody, in renal allograft recipients. Transplant Proc.
2009;41:3655-3661.
54. Langley RG, Papp K, Bissonnette R, et al. Safety proﬁle of intravenous and
subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the
treatment of plaque psoriasis: results of two randomized, double-blind,
placebo-controlled studies. Int J Dermatol. 2010;49:818-828.
55. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated
progressive multifocal leucoencephalopathy in patients treated with
rituximab, natalizumab, and efalizumab: a review from the Research
on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol.
2009;10:816-824.
56. Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic
therapy in systemic lupus erythematosus. BMC Med. 2014;12:30.Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL
Shows Deep Molecular Responses in Long-Term
PosteAllogeneic Stem Cell Transplantation Chronic Myeloid
Leukemia PatientsMaya Koren-Michowitz 1,2,*, Avichai Shimoni 1, Filomena Daraio 3,
Francesca Crasto 3, Roberta Lorenzatti 3, Yulia Volchek 1, Ninette Amariglio 1,
Enrico Gottardi 3, Giuseppe Saglio 3, Arnon Nagler 1,2
1Division of Hematology, Chaim Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga University Hospital, Turin,
ItalyArticle history:
Received 2 April 2015
Accepted 20 June 2015
Key Words:
Quantitative PCR
Stem cell transplantation
Chronic myeloid leukemiaa b s t r a c t
Real-time quantitative PCR (RT-qPCR) is commonly used for follow-up of chronic myeloid leukemia (CML)
patients treated with tyrosine kinase inhibitors, but its current sensitivity does not allow detection of very
low BCR-ABL levels. Therefore RT-qPCR negativity is not synonymous with complete molecular response.
Replicate RT-qPCR had shown increased sensitivity in tyrosine kinase inhibitoretreated patients and was,
therefore, used here to evaluate whether RT-qPCRenegative posteallogeneic stem cell transplantation (SCT)
patients harbor detectable disease. Samples from 12 patients were tested at 2 time points using 82 replicates
of BCR-ABL RT-qPCR. One patient (38 months after SCT) had detectable transcripts at baseline and none at the
follow-up test, done at a median of 107 months after SCT. This suggests cure from CML in the majority of
allogeneic SCT patients who have no transcripts detectable by replicate RT-qPCR for BCR-ABL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Treatment with ABL tyrosine kinase inhibitors (TKI) has
become the cornerstone of chronic myeloid leukemia (CML)
therapy in recent years. Chronic phase CML patients
achieving deep molecular responses (MR) on long-term TKI
therapy may be thought of as having a “functional” cure and
withholding TKI treatment in patients with continuous deep
responses is currently under intensive investigation [1,2].Nevertheless, allogeneic (Allo) stem cell transplantation
(SCT) is still the only modality with proven efﬁcacy in
advanced phase cases and is a valid option in TKI-resistant
cases. Absence of BCR-ABL transcripts after SCT with sensi-
tive methods (ie, achieving PCR negativity) correlates with
long-term disease-free survival, whereas re-emergence of
BCR-ABL transcripts has been shown to predict disease
relapse and is, therefore, used to trigger therapeutic in-
terventions, such as the addition of a TKI or donor lympho-
cyte infusion [3-6]. With the widespread use of PCR to detect
BCR-ABL transcripts, it has become clear that achieving PCR
negativity is not synonymous with molecular complete
response but rather depends on the sensitivity of themethod
used and technical variables, such as the RNA quality in each
speciﬁc sample [7]. Real-time quantitative PCR (RT-qPCR) is
the most commonly used method for follow-up of CML
